Pricing
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye.
Industries
Headquarters
Employees
Links
Org chart
Teams
Offices
Thomas Cavanagh
9 people · 0 jobs
2 people · 0 jobs
1 person · 0 jobs
HQ
0 people · 0 jobs
Peptone
2 followers
Tango Therapeutics
3 followers
FUJIFILM Diosynth Biotechnologies
27 followers
Cellares
5 followers
ContractPodAi
COMPASS Pathways
6 followers
QuellTX
Lendable
4 followers
Sanofi
330 followers
Gilead Sciences
177 followers
Regeneron
145 followers
Explore companies